Complement regulation

Vox Sanguinis

Volumn 74, Issue SUPPL. 2, 1998, Pages 291-302

  Meri, Seppo ^a,b   Jarva, H ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT;

ANGIONEUROTIC EDEMA; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; CONFERENCE PAPER; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PRIORITY JOURNAL;

EID: 0031853929     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1423-0410.1998.tb05434.x     Document Type: Conference Paper

References (118)

1. Holmskov U, Malhotra R, Sim RB, Jensenius JC; Collectins: collagenous C-type lectins of the innate immune defense system. Immunol Today 1994,15:67-74
2. Kaplan MH, Volanakis JE: Interaction of Creactive protein complexes with the complement system. I. Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and the choline phosphatides lecithin and sphingomyelin. J Immunol 1974, 112: 2135-2147
3. Clas FG, Schmid TG, Loos M: The role of the classical pathway for the bactericidal effect of normal human sera against gram-negative bacteria. Current topics in microbiology and immunology: Bacteria and complement. Edited by Loos M. Berlin, Springer-Verlag, 1985, pp. 19-72
4. Cooper NR, Jensen FC, Welsh RM, Oldstone MBA: Lysis of RNA tumor viruses by human serum: Direct antibody independent triggering of the classical complement pathway. J Exp Med 1976,144:970-984
5. Hirsch RL, Winkelstein JA, Griffin DE: The role of complement in viral infections. III. Activation of the classical and alternative complement pathways by Sindbis virus. J Immunol 1980,124:2507-2510
6. Matsushita M, Fujita T: Activation of the classical complement pathway by mannosebinding protein in association with a novel Cls-like serine protease. J Exp Med 1992, 176: 1497-1502
7. Thiel S, Vorup-Jensen T, Stover CM, Schwaeble W, Laursen SB, Poulsen K, Willis AC, Eggleton P, Hansen S, Holmskov U, Reid KBM, Jensenius JC: A second serine protease associated with mannan-binding lectin that activates complement. Nature 1997, 386: 506-510
8. Sumiya M, Super M, Tabona P, Levinsky RJ, Arai T, Turner MW, Summerfield JA: Molecular basis of opsonic defect in immunodeficient children. Lancet 1991, 337: 1569-1570
9. Garred P, Madsen HO, Hofmann B, Svejgaard A: Increased frequency of homozygosity of abnormal mannan-binding-protein alleles in patients with suspected immunodeficiency. Lancet 1995, 346: 941-943
10. Summerfield JA, Ryder S, Sumiya M, Thursz M, Gorchein A, Monteil MA, Turner MW: Mannose binding protein gene mutations associated with unusual and severe infections in adults. Lancet 1995, 345: 886-889
11. Summerfield JA, Sumiya M, Levin M, Turner MW: Association of mutations in mannose binding protein gene with childhood infection in consecutive hospital series. Lancet 1997, 314: 1229-1232
12. Nilsson T, Wiman B: Purification and characterization of human Cl-esterase inhibitor. Biochim Biophys Acta 1982, 705: 271-276
13. Harrison RA: Human Cl-inhibitor: improved isolation and preliminary structural characterization. Biochemistry 1983,22: 5001-5007
14. Bock SC, Skriver K, Nielsen E, Thogersen HC, Wiman B, Donaldson VH, Eddy RL, Marrinan J, Radziejewska E, Huber R, Shows TB, Magnusson S: Human Cl inhibitor: primary structure, cDNA cloning, and chromosomal localization. Biochemistry 1986, 25: 4292-4301
15. Carrell RW, Aulak KS, Owen MC: The molecular pathology of serpins. Mol Biol Med 1989,6:35-42
16. Carter PE, Dunbar B, Fothergill JE: Genomic and cDNA cloning of the human Cl inhibitor: Intron-exon junctions and comparison with other serpins. Eur J Biochem 1987, 173: 163-169
17. Circolo A, Strunk RC: Hereditary angioedema - understanding the basis of Cl inhibitor deficiency. Immunologist 1997, 5: 166-170
18. Chung LP, Bentley DR, Reid KBM: Molecular cloning and characterization of the cDNA coding for C4b-binding protein, a regulatory protein of the classical pathway of the human complement system. Biochem J 1985, 230: 133-141
19. Dahlbäck B, Smith CA, Müller-Eberhard HJ: Visualization of human C4b-binding protein and its complexes with vitamin K-dependent protein S and complement protein C4b. Proc Natl Acad Sci USA 1983, 80: 3461-3465
20. Hillarp A, Dahlbäck B: Cloning of cDNA coding for the beta chain of human complement component C4b-binding protein: Sequence homology with the alpha chain. Proc Natl Acad Sci USA 1990, 87: 1183-1187
21. Hillarp A, Dahlbäck B: Novel subunit in C4b-binding protein required for protein S binding. J Biol Chem 1988, 263: 12759-12764
22. Dahlbäck B: Protein S and C4b-binding protein: components involved in the regulation of the protein C anticoagulant system. Thromb Haemost 1991, 66: 49-61
23. Weiler JM, Daha MR, Austen KF, Fearon DT: Control of the amplification convertase of complement by the plasma protein beta 1H. Proc Natl Acad Sci USA 1976, 73: 3268-3272
24. Whaley K, Ruddy S: Modulation of C3b hemolytic activity by a plasma protein distinct from C3b inactivator. Science 1976, 193: 1011-1013
25. Høgåsen K, Jansen JH, Mollnes TE, Hovdenes J, Harboe M: Hereditary porcine membranoproliferative glomerulonephritis type II is caused by factor H deficiency. J Clin Invest 1995, 95: 1054-1061
26. West CD: Nephritic factors predispose to chronic glomerulonephritis. Am J Kidney Dis 1994, 24: 956-963
27. Kristensen T, Tack BF: Murine protein H is comprised of 20 repeating units, 61 amino acids in length. Proc Natl Acad Sci USA 1986, 83: 3963-3967
28. Jokiranta TS, Zipfel PF, Hakulinen J, Kühn S, Pangburn MK, Tamerius JD, S. M: Analysis of the recognition mechanism of the alternative pathway of complement by monoclonal anti-factor H antibodies: evidence for multiple interactions between H and surface bound C3b. FEBS Lett 1996, 393: 297-302
29. Sharma AK, Pangburn MK: Identification of three physically and functionally distinct binding sites for C3b in human complement factor H by deletion mutagenesis. Proc Natl Acad Sci USA 1996, 93: 10996-11001
30. DiScipio RG: Ultrastructures and interactions of complement factors H and I. J Immunol 1992, 149: 2592-2599
31. Men S, Pangbum MK: Discrimination between activators and nonactivators of alternative pathway of complement: regulation via a sialic acid/polyanion binding site on factor H. Proc Natl Acad Sci USA 1990, 87: 3982-3986
32. Blackmore TK, Sadlon TA, Ward HM, Lublin DM, Gordon DL: Identification of a heparin binding domain in the seventh short consensus repeat of complement factor H. J Immunol 1996, 157: 5422-5427
33. Zipfel PF, Skerka C: Complement factor H and related proteins: an expanding family of complement-regulatory proteins? Immunol Today 1994, 15: 121-126
34. Fritz IB, Burdzy K, Setchell B, Blaschnik O: Ram rete testis fluid contains a protein (clusterin) which influences cell-cell interactions in vitro. Biol Reprod 1983, 28: 1173-1188
35. Murphy BB, Kirszbaum L, Walker ID, d'Apice AJ: A newly identified normal human serum protein found in the SC5b-9 complex of complement and in the immune deposits in glomerulonephritis. J Clin Invest 1988, 81: 1858-1864
36. Jenne D, Tschopp J: Molecular structure and functional characteristics of a human complement cytolysis inhibitor found in blood and seminal plasma: Identity to sulfated glycoprotein 2, a constituent of rat testis fluid. Proc Natl Acad Sci USA 1989, 86: 7123-7127
37. deSilva HV, Harmony JA, Stuart WD, Gill CM, Robbins J: Apolipoprotein J: Structure and tissue distribution. Biochemistry 1990,29: 5380-5389
38. Väkevä A, Laurila P, Meri S: Codeposition of clusterin with the complement membrane attack complex in myocardial infarction. Immunol 1993, 80: 177-182
39. Duguid JR, Bohmont CW, Liu NG, Tourtellotte WW: Changes in brain gene expression shared by scrapie and Alzheimer's disease. Proc Natl Acad Sci USA 1989, 86: 7260-7264
40. McGeer PL, Rogers J: Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease. Neurology 1992, 42: 447-449
41. Kolb WP, Müller-Eberhard HJ: The membrane attack mechanism of complement. Isolation and subunit composition of the C5b-9 complex. J Exp Med 1975, 141: 724-735
42. Hayman EG, Engvall E, A'Hearn E, Barnes D, Pierschbacher M, Ruoslahti E: Cell attachment on replicas of SDS polyacrylamide gels reveals two adhesive plasma proteins. J Cell Biol 1982, 95: 20-23
43. Jenne D, Stanley KK: Molecular cloning of S protein, a link between complement, coagulation and cell-substrate adhesion. EMBO J 1985, 4: 3153-3157
44. Pytela R, Pierschbacher MD, Ruoslahti E: A 125/115-kDa cell surface receptor specific for vitronectin interacts with the arginine-glycineaspartic acid adhesion sequence derived from fibronectin. Proc Natl Acad Sci USA 1985, 82: 5766-5770
45. Ruoslahti E, Pierschbacher MD: New perspectives in cell adhesion: RGD and integrins. Science 1987, 238: 491-497
46. Podack ER, Kolb WP, Müller-Eberhard HJ: The SC5b-7 complex: Formation, isolation, properties and subunit composition. J Immunol 1977, 119: 2024-2029
47. Peitsch M, Preissner KT: The heparin binding domain of S-protein/vitronectin binds to complement components C7, C8 and C9 and perform from cytolytic T cells and inhibits their lytic activities. Biochemistry 1988, 27: 4103-4109
48. Savill J, Dransfield I, Hogg N, Haslett C: Vitronectin receptor-mediated phagocytosis of cells undergoing apoptosis. Nature 1990, 343: 170-173
49. Dykman TR, Cole JL, lida K, Atkinson JP: Polymorphism of human erythrocyte C3b/C4b receptor. Proc Natl Acad Sci USA 1983, 80: 1698-1702
50. Fearon DT: Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membranes. Proc. Natl. Acad. Sci. USA 1979, 76: 5867-5871
51. Reynes M, Aubert JP, Cohen JH, Audouin J, Trittet V, Diebold J, Kazatchkine MD: Human follicular dendritic cells express CRI, CR2 and CR3 complement receptor antigens. J Immunol 1985, 135: 2687-2694
52. Appay MD, Kazatchkine MD, Levi-Strauss M, Hinglais N, Bariety J: Expression of CR1 (CD35) mRNA in podocytes from adult and fetal human kidneys. Kidney Int 1990, 38: 289-293
53. Vedeler CA, Matre R: Peripheral nerve CR1 expresses in situ cofactor activity for degradation of C3b. J Neuroimmunol 1990, 26: 51-56
54. Fearon DT: Cellular receptors for fragments of the third component of complement. Immunol Today 1984, 5: 105-110
55. Weisman HF, Bartow T, Leppo MK, Marsh HC, Carson OR, Concino MF, Boyle MP, Roux KH, Weisfeldt ML, Fearon DT: Soluble human complement receptor type 1: In vivo inhibitor of complement suppressing postischemic myocardial inflammation and necrosis. Science 1990, 249: 146-151
56. Huffman EM: Inhibition of complement by a substance isolated from human erythrocytes. I. Extraction from human erythrocyte stromata. Immunochemistry 1969, 6: 391-403
57. Nicholson-Weller A, Burge J, Austen KF: Purification from guinea pig erythrocyte stroma of a decay-accelerating factor for the classical C3 convertase, C4b2a. J Immunol 1981, 127: 2035-2039
58. Nicholson-Weller A, Burge J, Fearon DT, Weller PF, Austen KF: Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J. Immunol. 1982, 129: 184-189
59. Kinoshita T, Medof ME, Silber R, Nussenzweig V: Distribution of decay accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria. J Exp Med 1985, 162: 75-
60. Nicholson-Weller A, March JP, Rosen CE, Spicer DP, Austen KF: Surface membrane expression by human blood leukocytes and platelets of decay accelerating factor, a regulatory protein of the complement system. Blood 1985, 65: 1237-1244
61. Medof ME, Walter EI, Rutgers JL, Knowles DM, Nussenzweig V: Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids. J Exp Med 1987, 165: 848-864
62. Lublin DM, Krsek-Staples J, Pangburn MK, Atkinson JP: Biosynthesis and glycosylation of the human complement regulatory protein decay-accelerating factor. J Immunol 1986, 137: 1629-1635
63. Lublin DM, Liszewski MK, Post TW, Arce MA, LeBeau MM, Rebentisch MB, Lemons LS, Seya T, Atkinson JP: Molecular cloning and chromosomal localization of human membrane cofactor protein (MCP). J Exp Med 1988, 168:181-194
64. Nicholson-Weller A, March JP, Rosenfeld SI, Austen KF: Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein decay-accelerating factor. Proc Natl Acad Sci USA 1983, 80: 5066-5070
65. Fujita T, Inoue T, Ogawa K, lida K, Tamura N: The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 converties by dissociating C2a and Bb. J Exp Med 1987, 166:1221-1228
66. Telen MJ, Hall SE, Green AM, Moulds JJ, Rosse WF: Identification of human erythrocyte blood group antigens on decay-accelerating factor (DAF) and an erythrocyte phenotype negative for DAF. J Exp Med 1988, 167: 1993-1998
67. Pangburn MK, Schreiber RD, Müller-Eberhard HJ: Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci USA 1983, 80: 5430- 5434
68. Nowicki B, Hart A, Coyne KE, Lublin DM, Nowicki S: Short consensus repeat-3 domain of recombinant decay-accelerating factor is recognized by Escherichia coli recombinant Dr adhesion in a model of a cell-cell interaction. J Exp Med 1993, 178: 2115-2121
69. Bergeisen JM, Chan M, Solomon K, St.John NF, Lin H, Finberg RW: Decay-accelerating factor, a glycosylphosphatidylinositol-anchored complement regulatory protein, is a receptor for several echoviruses. Proc Natl Acad Sci USA 1994, 91: 6245-6248
70. Horta MFM, Ramalho-Pinto FJ: Role of human decay-accelerating factor in the evasion of Schistosoma mansoni from the complement-mediated killing in vitro. J Exp Med 1991, 174:1399-1406
71. Bjørge L, Hakulinen J, Wahlström T, Matre R, Meri S: Complement regulatory proteins in ovarian malignancies. Int J Cancer 1997, 70: 14-25
72. McCurry KR, Kooyman DL, Alvarado CG, Cotterell AH, Martin MJ, Logan JS, Platt JL: Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury. Nature Med 1995, 1: 423-427
73. White DJ, Yannoutsos N: Production of pigs transgenic for human DAF to overcome complement-mediated hyperacute xenograft rejection in man. Res Immunol 1996, 147: 88-94
74. Seya T, Turner JR, Atkinson JP: Purification and characterization of a membrane protein (gp45-70) that is a cofactor for cleavage of C3b and C4b. J. Exp. Med. 1986, 163: 837- 855
75. Cole J, Housley GA, Dykman TR, MacDermott RP, Atkinson JP: Identification of an additional class of C3-binding membrane proteins of human peripheral blood leukocytes and cell lines. Proc Natl Acad Sci USA 1985, 83: 859-863
76. Yu G, Holers VM, Seya T, Ballard L, Atkinson JP: Identification of a third component of complement-binding glycoprotein of human platelets. J Clin Invest 1986, 78: 494-501
77. Seya T, Ballard L, Bora NS, Kumar V, Cui W, Atkinson JP: Distribution of membrane cofactor protein (MCP) of complement on human peripheral blood cells. Eur J Immunol 1988, 18: 1289-1294
78. McNeamey T, Ballard L, Seya T, Atkinson JP: Membrane cofactor protein of complement is present on human fibroblast, epithelial and endothelial cells. J Clin Invest 1989, 84: 538- 545
79. Purcell DFJ, McKenzie IFC, Lublin DM, Johnson PM, Atkinson JP: The human cellsurface glycoproteins HuLy-m5, membrane cofactor protein (MCP) of the complement system, and trophoblast-leukocyte common (TLX) antigen are CD46. Immunology 1990, 70: 155-161
80. Ballard L, Seya T, Teckman J, Lublin DM, Atkinson JP: A polymorphism of the complement regulatory protein MCP (membrane cofactor protein of gp45-70). J Immunol 1987, 138: 3850-3855
81. Naniche D, Varior-Krishnan G, Cervoni F, Wild TF, Rossi B, Rabourdin-Combe C, Gerlier D: Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J Virol 1993, 67: 6025-6032
82. Dorig RE, Marcil A, Chopra A, Richardson CD: The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell 1993, 75: 295-305
83. Okada N, Liszewski MK, Atkinson JP, Caparon M: Membrane cofactor protein (CD46) is a keratinocyte receptor for the M protein of the group A streptococcus. Proc Natl Acad Sci USA 1995, 92: 2489-2493
84. Horstmann RD, Sievertsen HJ, Knobloch J, Fischetti VA: Antiphagocytic activity of streptococcal M protein: selective binding of complement control protein factor H. Proc Natl Acad Sci USA 1988, 85: 1657-1661
85. Sugita Y, Nakano Y, Tomita M: Isolation from human erythrocytes of a new membrane protein which inhibits the formation of complement transmembrane channels. J. Biochem. (Tokyo) 1988, 104: 633-637
86. Okada N, Harada R, Fujita T, Okada H: A novel membrane glycoprotein capable of inhibiting membrane attack by homologous complement. Int. Immunol. 1989, 1: 205-208
87. Holguin MH, Fredrick LR, Bernshaw NJ, Wilcox LA, Parker CJ: Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria. J. Clin. Invest. 1989, 84: 7-17
88. Meri S, Morgan BP, Davies A, Daniels RH, Olavesen MG, Waldmann H, Lachmann PJ: Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalyzed insertion of C9 into lipid bilayers. Immunology 1990, 71: 1-9
89. Davies A, Simmons DL, Hale G, Harrison RA, Tighe H, Lachmann PJ, Waldmann H: CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J. Exp. Med. 1989, 170: 637-654
90. Nose M, Katoh M, Okada N, Kyogoku M, Okada H: Tissue distribution of HRF20, a novel factor preventing the membrane attack of homologous complement, and its predominant expression on endothelial cells in vivo. Immunology 1990, 70: 145-149
91. Brooimans RA, Van der Ark AAJ, Tomita M, Van Es LA, Dana MR; CD59 expressed by human endothelial cells functions as a protective molecule against complement-mediated lysis. Eur. J. Immunol. 1992, 22: 791-797
92. Men S, Mattila P, Renkonen R: Regulation of CD59 expression on the human endothelial cell line EA.hy 926. Eur. J. Immunol. 1993, 23: 2511-2516
93. Meri S, Waldmann H, Lachmann PJ: Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues. Lab. Invest, 1991, 65: 532-537
94. Rooney IA, Morgan BP: Characterization of the membrane attack complex inhibitory protein CD59 antigen on human amniotic cells and in amniotic fluid. Immunology 1992, 76: 541-547
95. Väkevä A, Laurila P, Meri S: Loss of protectin (CD59) is associated with deposition of the complement membrane attack complex in myocardial infarction. Lab. Invest. 1992, 67: 608-616
96. McGeer PL, Walker DG, Akiyama H, Kawamata T, Guan AL, Parker CJ, Okada N, McGeer EG: Detection of the membrane inhibitor of reactive lysis (CD59) in diseased neurons of Alzheimer brain. Brain Res. 1991, 544: 315-319
97. Hakulinen J, Meri S: Expression and function of the complement membrane attack complex inhibitor CD59 protectin on human breast cancer cells. Lab. Invest. 1994,71:820-827
98. Mäenpää A, Junnikkala S, Hakulinen J, Timonen T, Meri S: Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55) and protectin (CD59) in human malignant gliomas, Am. J. Pathol. 1996,148:1139-1152
99. Tandon N, Morgan BP, Weetman AP: Expression and function of membrane attack complex inhibitory proteins on thyroid follicular cells. Immunology 1992,75:372-377
100. Väkevä A, Jauhiainen M, Ehnholm C, Lehto T, Meri S: High density lipoproteins can act as carriers of glycophosphoinositollipid-anchored CD59 in human plasma. Immunology 1994, 82:28-33
101. Hakulinen J, Meri S: Shedding and enrichment of the glycolipid-anchored complement lysis inhibitor protectin (CD59) into milk fat globules. Immunology 1995,85:495-501
102. Okada H, Okada N, Hideshima T: HRF20, a membrane inhibitor of complement attack, does not protect cells from the cytotoxic reaction by lymphokine activated killer cells. Biochem. Biophys. Res. Commun. 1990,171: 717-721
103. Petranka JG, Fleenor DE, Sykes K, Kaufman RE, Rosse WF: Structure of the CD59-encoding gene: Further evidence of a relationship to murine lymphocyte antigen Ly-6 protein. Proc Natl Acad Sci 1992,89:7876-7879
104. Tone M, Walsh LA, Waldmann H: Gene structure of human CD59 gene and demonstration that discrete mRNAs are generated by alternative polyadenylation. J Mol Biol 1992, 227:971-976
105. Wang Y, Dang J, Johnson LK, Selhamer JJ, Doe WF: Structure of the human urokinase receptor gene and its similarity to CD59 and the Ly-6 family. Eur J Biochem 1995,227:116-122
106. Ploug M, Ellis V: Structure-function relationship in the receptor for urokinase-type plasminogen activator. Comparison to other members of the Ly-6 family and snake venom alpha-neurotoxins. FEBS Lett. 1994,349:163-168
107. Fletcher CM, Harrison RA, Lachmann PJ, Neuhaus D: Structure of a soluble, glycosylated form of the complement regulatory protein CD59. Structure 1994,2:185-199
108. Kieffer B, Driscoll PC, Campbell ID, Willis AC, van der Merwe PA, Davis SJ: Three-di mensional solution structure of the extracellular region of the complement regulatory protein CD59, a new cell-surface protein related to snake venom neurotoxins. Biochemistry 1994, 33:4471-4482
109. Rollins SA, Zhao J, Ninomiya H, Sims PJ: Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9. J. Immunol. 1991, 146:2345-2351
110. Ninomiya H, Sims P: The human complement regulatory protein CD59 binds to the alphachain of C8 and to the "b" domain of C9. J. Biol. Chem. 1992, 267:13675-13680
111. Stefanova I, Horejsi V, Ansotegui IJ, Knapp W, Stockinger H: GPI-anchored cell-surface molecules complexed to protein tyrosine kinases. Science 1991,254:1016-1019
112. Brown DA, Rose JK: Sorting of GPI-anchored proteins to glycolipid-enriched membrane subdomains during transport to the apical cell surface. Cell 1992,68:533-544
113. Sargiacomo M, Sudol M, Tang Z, Lisanti MP: Signal transducing molecules and glycosyl-phosphatidylinositol-linked proteins form a caveolin-rich insoluble complex in MDCK cells. J Cell Biol 1993,122:789-807
114. Rosse WF: Paroxysmal nocturnal hemoglobinuria as a molecular disease. Medicine 1997, 76: 63-93
115. Takeda J, Miyata T, Kawagoe K, Iida Y, Endo Y, Fujita T, Takahashi M, Kitani T, Kinoshita T: Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 1993,73:703-711
116. Yamashina M, Ueda E, Kinoshita T, Takami T, Ojima A, Ono H, Tanaka H, Kondo N, Orii T, Okada N, Okada H, Inoue K, Kitani T: Inherited complete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 1990,323:1184-1189
117. Telen MJ, Green AM: The Inab phenotype: Characterization of the membrane protein and complement regulatory defect. Blood 1989, 74:437-441
118. Sims PJ, Wiedmer T: The response of human platelets to activated components of the complement system. Immunol Today 1991,12: 338-342